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Background: Measurement of plasma levels of brain natriuretic peptide (BNP) to guide treatment of patients with chronic heart failure (HF) has 
been investigated in several randomized controlled trials (RCTs). The aim of this study was to examine the overall effect of BNP-guided therapy on 
cardiovascular outcomes in patients with chronic HF.
methods: We searched MEDLINE, EMBASE, Cochrane databases, and conference proceedings for RCTs from January 2001 to August 2012. Studies 
were included if they compared BNP-guided therapy vs. standard care in patients with chronic HF. The pooled effects were calculated using fixed-
effects model (Mantel-Haenszel method).
results: Eight RCTs with a total of 2,056 patients (1,037 BNP-guided and 1,019 standard care) were included in this study. Mean follow-up 
duration for each study ranged from 9 to 24 months. Overall, there was a significantly lower risk of all-cause mortality (risk ratio [RR] 0.81, 95% 
confidence interval [CI] 0.68 to 0.97, p=0.02) in the BNP-guided therapy group compared with the standard care group. BNP-guided HF therapy was 
also associated with a significantly lower rate of hospital admission for various causes (RR 0.81, 95% CI 0.72 to 0.91, p<0.001). Stratified analysis 
of our study showed that the benefit of biomarker-guidance was more pronounced in multicenter trials compared to single center studies, studies 
using NT-proBNP instead of BNP, and studies with follow-up duration >12 months compared with studies with shorter follow-up.
conclusions: BNP-guided therapy is associated with significant reductions in all-cause mortality and hospital admission compared with standard 
care in patients with chronic HF.
